HUP9702034A2 - Inhibitors of leukocita-adhesion and vla-4-antagonists and pharmaceutical compositions containing them - Google Patents

Inhibitors of leukocita-adhesion and vla-4-antagonists and pharmaceutical compositions containing them

Info

Publication number
HUP9702034A2
HUP9702034A2 HU9702034A HUP9702034A HUP9702034A2 HU P9702034 A2 HUP9702034 A2 HU P9702034A2 HU 9702034 A HU9702034 A HU 9702034A HU P9702034 A HUP9702034 A HU P9702034A HU P9702034 A2 HUP9702034 A2 HU P9702034A2
Authority
HU
Hungary
Prior art keywords
compounds
cell
general formula
vla
adhesion
Prior art date
Application number
HU9702034A
Other languages
Hungarian (hu)
Inventor
Christoph Hüls
Dirk Seiffge
Hans Ulrich Stilz
Volkmar Wehner
Original Assignee
Hoechst Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Aktiengesellschaft filed Critical Hoechst Aktiengesellschaft
Publication of HU9702034D0 publication Critical patent/HU9702034D0/en
Publication of HUP9702034A2 publication Critical patent/HUP9702034A2/en
Publication of HUP9702034A3 publication Critical patent/HUP9702034A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A találmány szerinti vegyületek (I) általánős képletébenW, Y, A, B, D és E jelentése egymástól függetlenül szerves csőpőrt,Zjelentése őxigén- vagy kénatőm vagy szerves csőpőrt,Rjelentése hidrőgénatőm vagy szerves csőpőrt,b, c, d és f értéke egymástól függetlenül 0 vagy 1, azzal amegkötéssel, hőgy egyidejűleg legalább egyikük értéke 0-tól eltérő, ése, g és h értéke egymástól függetlenül 0, 1, 2, 3, 4, 5 vagy 6.A találmány tárgykörébe tartőznak tővábbá (I) általánős képletűvegyületek és e vegyületeket tartalmazó gyógyászati készítményekalkalmazása őlyan betegségek kezelésére vagy megelőzésére, amelyeketleűkőciták nem kívánatős mértékű adhéziója és/vagy migrációja őkőzvagy azzal kapcsőlatősak, vagy amelyeknél a VLA-4-receptőrők ésligandűmaik kapcsőlatán alapűló sejt-sejt vagy sejt-mátrixkölcsönhatásők szerepet játszanak, így gyűlladásős főlyamatők, reűmásízületi gyűlladásők vagy allergiás megbetegedések esetén. A találmányvőnatkőzik tővábbá az (I) általánős képletű vegyületek alkalmazásárailyen betegségeknél használandó gyógyászati készítményekelőállítására.ŕIn the general formula (I) of the compounds according to the invention, W, Y, A, B, D and E independently represent organic pipe powder, Z represents an oxygen or sulfur atom or organic pipe powder, R represents a hydrogen atom or organic pipe powder, the values of b, c, d and f are independent of each other 0 or 1, with the proviso that, at the same time, at least one of them has a value other than 0, and the values of g and h are independently 0, 1, 2, 3, 4, 5 or 6. The scope of the invention further includes compounds of general formula (I) and the use of medicinal preparations containing these compounds for the treatment or prevention of diseases which are caused by or are associated with an undesirable level of adhesion and/or migration of amyloid cells, or in which cell-cell or cell-matrix interactions based on the binding of VLA-4 receptors and their ligands play a role, such as inflammatory headaches, rheumatoid arthritis in case of inflammatory or allergic diseases. The invention further extends to the use of compounds of general formula (I) for the production of medicinal preparations to be used in such diseases.

HU9702034A 1996-11-15 1997-11-14 Inhibitors of leukocita-adhesion and vla-4-antagonists and pharmaceutical compositions containing them HUP9702034A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19647382A DE19647382A1 (en) 1996-11-15 1996-11-15 Heterocycles as inhibitors of leukocyte adhesion and VLA-4 antagonists

Publications (3)

Publication Number Publication Date
HU9702034D0 HU9702034D0 (en) 1998-01-28
HUP9702034A2 true HUP9702034A2 (en) 1998-07-28
HUP9702034A3 HUP9702034A3 (en) 1998-12-28

Family

ID=7811832

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9702034A HUP9702034A3 (en) 1996-11-15 1997-11-14 Inhibitors of leukocita-adhesion and vla-4-antagonists and pharmaceutical compositions containing them

Country Status (28)

Country Link
US (2) US5998447A (en)
EP (1) EP0842944B1 (en)
JP (1) JP4510160B2 (en)
CN (1) CN1133647C (en)
AR (1) AR010066A1 (en)
AT (1) ATE244725T1 (en)
AU (1) AU736595B2 (en)
BR (1) BR9705726A (en)
CA (1) CA2220822A1 (en)
CZ (1) CZ292521B6 (en)
DE (2) DE19647382A1 (en)
DK (1) DK0842944T3 (en)
ES (1) ES2202533T3 (en)
HR (1) HRP970606B1 (en)
HU (1) HUP9702034A3 (en)
IL (1) IL122186A (en)
MX (1) MX9708781A (en)
MY (1) MY118176A (en)
NO (1) NO317242B1 (en)
NZ (1) NZ329177A (en)
PL (2) PL323130A1 (en)
PT (1) PT842944E (en)
RU (1) RU2220977C2 (en)
SI (1) SI0842944T1 (en)
SK (1) SK284349B6 (en)
TR (1) TR199701356A2 (en)
TW (1) TW580501B (en)
ZA (1) ZA9710245B (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19647381A1 (en) 1996-11-15 1998-05-20 Hoechst Ag New heterocycles as leukocyte adhesion inhibitors and VLA-4 antagonists
DE19647380A1 (en) * 1996-11-15 1998-05-20 Hoechst Ag 5-ring heterocycles as inhibitors of leukocyte adhesion and VLA-4 antagonists
DE19647382A1 (en) 1996-11-15 1998-05-20 Hoechst Ag Heterocycles as inhibitors of leukocyte adhesion and VLA-4 antagonists
DE19741235A1 (en) 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Novel imidazolidine derivatives, their preparation, their use and pharmaceutical compositions containing them
DE19741873A1 (en) * 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh New 5-ring heterocycles, their preparation, their use and pharmaceutical preparations containing them
DE19751251A1 (en) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituted imidazolidine derivatives, their manufacture, their use and pharmaceutical preparations containing them
DE19821483A1 (en) * 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh New imidazolidine derivatives useful as leukocyte adhesion and migration inhibitors and/or VLA-4 receptor antagonists for treating E.G. inflammatory and allergic disorders
NZ509241A (en) 1998-08-07 2003-08-29 Du Pont Pharm Co Succinoylamino lactams as inhibitors of alpha-beta protein production
HRP990246A2 (en) 1998-08-07 2000-06-30 Du Pont Pharm Co Succinoylamino benzodiazepines as inhibitors of a beta protein production
AU778005B2 (en) 1998-12-24 2004-11-11 Bristol-Myers Squibb Pharma Company Succinoylamino benzodiazepines as inhibitors of Abeta protein production
DE19922462A1 (en) * 1999-05-17 2000-11-23 Aventis Pharma Gmbh New phenylureidobenzyl-substituted spiro-imidazolidinedione derivatives, are inhibitors of leukocyte adhesion or migration or VLA-4 receptors, useful e.g. for treating inflammatory or allergic disease
US6503902B2 (en) 1999-09-13 2003-01-07 Bristol-Myers Squibb Pharma Company Hydroxyalkanoylaminolactams and related structures as inhibitors of a β protein production
US6960576B2 (en) 1999-09-13 2005-11-01 Bristol-Myers Squibb Pharma Company Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production
WO2001027091A1 (en) 1999-10-08 2001-04-19 Du Pont Pharmaceuticals Company AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
EP1244656A1 (en) 1999-12-28 2002-10-02 Pfizer Products Inc. Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
AU2882801A (en) * 2000-01-28 2001-08-07 Kaken Pharmaceutical Co., Ltd. Azepine derivatives
JP2003523345A (en) 2000-02-17 2003-08-05 ブリストル−マイヤーズ スクイブ ファーマ カンパニー Succinoylamino carbocycles and heterocycles as inhibitors of Aβ protein production
US6495540B2 (en) 2000-03-28 2002-12-17 Bristol - Myers Squibb Pharma Company Lactams as inhibitors of A-β protein production
JP2004508289A (en) 2000-04-03 2004-03-18 デュポン　ファーマシューティカルズ　カンパニー Cyclic lactams as inhibitors of Aβ protein production
EP1268433A1 (en) 2000-04-03 2003-01-02 Bristol-Myers Squibb Pharma Company Cyclic lactams as inhibitors of a-beta-protein production
JP2004500419A (en) 2000-04-11 2004-01-08 デュポン　ファーマシューティカルズ　カンパニー Substituted lactams as Aβ protein production inhibitors
NZ516746A (en) 2000-06-01 2004-02-27 Bristol Myers Squibb Pharma Lactams substituted by cyclic succinates as inhibitors of A-beta protein production
JP2004516237A (en) * 2000-06-21 2004-06-03 ブリストル−マイヤーズ・スクイブ・ファーマ・カンパニー Piperidine amides as modulators of chemokine receptor activity
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
DE10111877A1 (en) 2001-03-10 2002-09-12 Aventis Pharma Gmbh Novel imidazolidine derivatives, their preparation, their use and pharmaceutical compositions containing them
DE10137595A1 (en) * 2001-08-01 2003-02-13 Aventis Pharma Gmbh New 3-alkylaminoalkyl-imdazolidin-4-one derivatives, are VLA-4 receptor and leukocyte adhesion and/or migration inhibitors, useful e.g. for treating inflammatory, allergic, autoimmune or cardiovascular disease
TW200307667A (en) * 2002-05-06 2003-12-16 Bristol Myers Squibb Co Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors
KR101155335B1 (en) * 2005-01-07 2012-06-11 엘지전자 주식회사 Multimedia message service operating method for mobile communication terminal
US7630761B2 (en) * 2005-11-04 2009-12-08 Cardiac Pacemakers, Inc. Method and apparatus for modifying tissue to improve electrical stimulation efficacy
CA2714335A1 (en) 2007-02-20 2008-08-28 Merrimack Pharmaceuticals, Inc. Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
AU2009234253C1 (en) 2008-04-11 2015-05-07 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
WO2009131957A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising oxadiazole derivatives
US8236838B2 (en) * 2008-04-21 2012-08-07 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
WO2009131947A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising pyridazine derivatives
US20090264433A1 (en) * 2008-04-21 2009-10-22 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Triazine Derivatives
US8759384B2 (en) * 2008-05-12 2014-06-24 David J. Bearss Oxo-imidazolyl compounds
JP2012503005A (en) * 2008-09-19 2012-02-02 インスティテュート フォア ワンワールド ヘルス Compounds, compositions and methods comprising imidazole derivatives and triazole derivatives.
DE102009012314A1 (en) 2009-03-09 2010-09-16 Bayer Schering Pharma Aktiengesellschaft Oxo-heterocyclic substituted alkylcarboxylic acids and their use
US8511216B2 (en) * 2009-03-30 2013-08-20 Kanzaki Kokyukoki Mfg. Co., Ltd. Hydraulic actuator unit
US8343976B2 (en) * 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
US20120258093A1 (en) 2009-08-20 2012-10-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
CA2816016A1 (en) 2010-10-25 2012-05-10 Elan Pharmaceuticals, Inc. Methods for determining differences in alpha-4 integrin activity by correlating differences in svcam and/or smadcam levels
CA3121202A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
US20240301512A1 (en) 2021-01-29 2024-09-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of assessing the risk of developing progressive multifocal leukoencephalopathy in patients treated with vla-4 antagonists

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993013798A1 (en) * 1992-01-13 1993-07-22 Biogen, Inc. Treatment for asthma
DE4224414A1 (en) * 1992-07-24 1994-01-27 Cassella Ag Phenylimidazolidine derivatives, their preparation and their use
EP0677060A1 (en) * 1993-01-08 1995-10-18 Tanabe Seiyaku Co., Ltd. Peptide inhibitors of cell adhesion
DE4427979A1 (en) * 1993-11-15 1996-02-15 Cassella Ag Substituted 5-ring heterocycles, their preparation and their use
WO1995015973A1 (en) * 1993-12-06 1995-06-15 Cytel Corporation Cs-1 peptidomimetics, compositions and methods of using the same
EP0767674A4 (en) * 1994-06-29 1999-06-16 Texas Biotechnology Corp Process to inhibit binding of the integrin alpha 4 beta 1 to vcam-1 or fibronectin
US5811391A (en) * 1994-08-25 1998-09-22 Cytel Corporation Cyclic CS-1 peptidomimetics, compositions and methods of using same
GB9524630D0 (en) * 1994-12-24 1996-01-31 Zeneca Ltd Chemical compounds
US6306840B1 (en) * 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
DK0796855T3 (en) * 1996-03-20 2002-05-27 Hoechst Ag Inhibitors of bone resorption and vitronectin receptor antagonists
DE19647382A1 (en) 1996-11-15 1998-05-20 Hoechst Ag Heterocycles as inhibitors of leukocyte adhesion and VLA-4 antagonists
DE19741235A1 (en) * 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Novel imidazolidine derivatives, their preparation, their use and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
SI0842944T1 (en) 2004-02-29
EP0842944A3 (en) 1999-02-24
US5998447A (en) 1999-12-07
RU2220977C2 (en) 2004-01-10
IL122186A (en) 2003-05-29
CA2220822A1 (en) 1998-05-15
JP4510160B2 (en) 2010-07-21
EP0842944A2 (en) 1998-05-20
PL188042B1 (en) 2004-11-30
NO975245L (en) 1998-05-18
HU9702034D0 (en) 1998-01-28
SK284349B6 (en) 2005-02-04
EP0842944B1 (en) 2003-07-09
AR010066A1 (en) 2000-05-17
DE59710411D1 (en) 2003-08-14
DE19647382A1 (en) 1998-05-20
IL122186A0 (en) 1998-04-05
PL323130A1 (en) 1998-05-25
ATE244725T1 (en) 2003-07-15
ES2202533T3 (en) 2004-04-01
HRP970606A2 (en) 1998-08-31
NZ329177A (en) 1998-11-25
AU4525797A (en) 1998-05-21
TW580501B (en) 2004-03-21
ZA9710245B (en) 1998-05-13
SK152597A3 (en) 1998-06-03
JPH10147574A (en) 1998-06-02
NO317242B1 (en) 2004-09-27
CZ292521B6 (en) 2003-10-15
US6514952B1 (en) 2003-02-04
CN1133647C (en) 2004-01-07
MY118176A (en) 2004-09-30
TR199701356A3 (en) 1998-06-22
NO975245D0 (en) 1997-11-14
BR9705726A (en) 1999-07-20
CZ360097A3 (en) 1998-06-17
PT842944E (en) 2003-11-28
DK0842944T3 (en) 2003-10-27
CN1193022A (en) 1998-09-16
HUP9702034A3 (en) 1998-12-28
TR199701356A2 (en) 1998-06-22
AU736595B2 (en) 2001-08-02
MX9708781A (en) 1998-05-31
HRP970606B1 (en) 2003-08-31

Similar Documents

Publication Publication Date Title
HUP9702035A2 (en) Inhibitors of leukocita-adhesion- and vla-4-antagonists and pharmaceutical compositions containing them
HUP9702036A1 (en) Inhibitors of leucocita-adhesion and wla-4-antagonists and pharmaceutical compositions containing them
HUP9702034A2 (en) Inhibitors of leukocita-adhesion and vla-4-antagonists and pharmaceutical compositions containing them
HUP0102477A2 (en) Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases and pharmaceutical compositions containing the compounds
HUP0102475A2 (en) Novel acyl pseudodipeptides, preparation method and pharmaceutical compositions containing same
NO942064L (en) inhibitors
HUP0004529A2 (en) Sulfonilated dipeptide-compounds which inhibit leukocyte adhesion mediated by vla-4, pharmaceutical compositions comprising thereof and their use
WO2004098518A3 (en) Pyrazole-amide compounds useful as kinase inhibitors
FR2528038B2 (en) BENZHYDRYLSULFINYLACETAMIDE DERIVATIVES AND THEIR THERAPEUTIC USE
EA200601830A1 (en) ORT-SUBSTITUTED ARYL OR HETEROARYL AMIDAL COMPOUNDS
TR199900920T2 (en) Naphthiridin t�revleri.
HUP0003250A1 (en) Potassium channel inhibitor indane derivatives and pharmaceutical compositions containing the same
DK0873050T3 (en) Pharmaceutical compositions for the prevention and treatment of ulcerative colitis
DE69533264D1 (en) INHIBITORS OF IL-6 ACTIVITY
ES477653A1 (en) New amino sugar derivatives, their preparation and amylase inhibitors containing them.
HUP0303107A2 (en) Compounds useful in the treatment of inflammatory diseases, process for their preparation and pharmaceutical compositions containing them
HUP0002050A2 (en) Substituted imidazole compounds, process for producing them, pharmaceutical compositions containing them and their use
HUP9901590A2 (en) Substituted aza- and diazacycloheptane and cyclooctane derivatives, use thereof, pharmaceutical compositions containing these compounds
HUP0102723A2 (en) New diphenylurea derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0000762A2 (en) 2-amino-6-(2-substituted-4-phenoxy)-substituted-pyridines, and pharmaceutical compositions containing them
IS7616A (en) Cell adhesion-suppressing anti-inflammatory and immunosuppressive compounds
NO944946D0 (en) Branched-amino-substituted thiazoles, processes for their preparation and pharmaceutical compositions containing them
ATE181056T1 (en) ARYLESTIC ACID DERIVATIVES AND THEIR USE AS FUNGICIDES
HUP0002442A2 (en) N-linked ureas and carbamates of heterocyclic thioesters and pharmaceutical compositions containing them
ES8106891A1 (en) 2-Hydroxyalkyl-3,4,5,trihydroxy piperidines, processes for their preparation and their use as medicaments.

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees